OverviewChartNewsTraderScreen

BVT Knock-Out GNMSF/  DE000VV9GTC1  /

Frankfurt Zert./VONT
2024-05-21  2:02:33 PM Chg.+0.590 Bid3:25:06 PM Ask3:25:06 PM Underlying Strike price Expiration date Option type
27.560EUR +2.19% 27.590
Bid Size: 8,000		 27.610
Ask Size: 8,000		 Genmab A/S 4,067.42 DKK 2078-12-31 Put
GlobeNewswire 12:45 PM BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire 05-14 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...
GlobeNewswire 05-14 Immatics Announces First Quarter 2024 Financial Results and Business Update
GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 05-02 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire 04-03 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 03-11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 03-07 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 03-06 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 03-04 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire 02-14 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report
GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 01-31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 01-22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire 01-09 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-21 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 2023-12-18 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda